Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by


Meta-analysis consolidates evidence against PSA-based screening

PSA test

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.

EMBRACA results demonstrate talazoparib advanced breast cancer benefits

Breast cancer_silhouette

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.

Latest headlines

19-09-2018 | Myelodysplastic syndrome | News

Persistent mutations post-transplant predict MDS disease progression

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

18-09-2018 | Supportive care | News

Allogeneic HSCT-treated patients often receive medically intense end-of-life care

A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.

18-09-2018 | EMA | News

Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

In depth

27-04-2018 | Adolescents and young adults | Feature | Article

ACCELERATE-ing access to drugs for adolescents with cancer

medwireNews spoke to Miranda Fidler, from the International Agency for Research on Cancer, and Simon Davies, from Teen Cancer America, about the ACCELERATE working group's proposal to improve adolescent patients’ access to new cancer drugs.

Click for the accompanying news story

SUMIT: Selumetinib in metastatic uveal melanoma

This edition of the medwireNews podcast focuses on a recent trial of the MEK inhibitor selumetinib in metastatic uveal melanoma. Advisory Board member and study author Paul Nathan outlines the findings and discusses the wider implications.

Expert comment: AMPLE trial

Listen to Fabien Maldonado, from Vanderbilt University Medical Center in Nashville, Tennessee, USA, give his views on the AMPLE trial, published in JAMA, which aimed to establish the more effective technique for reducing the number of hospitalization days in patients with malignant pleural effusion.

image credits